FDA biotech approvals

Publicly traded biotech companies to monitor are increasingly shaping the strategic direction of the U.S. life sciences market. With capital markets gradually stabilizing after recent volatility, investors and executives are reassessing pipeline durability, regulatory milestones, and commercialization readiness. Companies with differentiated platforms and disciplined capital allocation are emerging as relative outperformers. In 2026, scrutiny is … Read more